O2matic device shows promise

COPENHAGEN and AURORA, Colo. – O2matic, a Danish medical device company focused on developing next-generation oxygen therapy and monitoring technologies, has announced that its proprietary technology is the subject of research led by Adit Ginde, MD, professor of emergency medicine and anesthesiology at the University of Colorado School of Medicine. Dr. Ginde and his team’s work has paved the way for the SAVE-O2 trial, a multi-center randomized clinical trial funded by the U.S. Department of Defense that focuses on redefining oxygen requirements in critically ill trauma patients through targeting normoxemia. Preliminary results from analyzing data from approximately 12,000 randomized patients have shown manually targeting normoxemia successfully reduces hyperoxemia without increasing hypoxemia, resulting in lower mortality rates, shortened hospital stays, and decreased supplemental oxygen requirements. “We at O2matic are deeply honored to be part of this significant study and eagerly anticipate the potential impact of our technology on acute and trauma patients,” said Arnt Lund, O2matic’s CEO. “We are also grateful to the IDE sponsor for this study, IDTS Medical, Inc. and its CEO, Mario Nozzarella, who guided us through the U.S. Food and Drug Administration Investigational Device Exemption (US FDA IDE) process and received our final (non-conditional) letter regarding the submission G230325/A001 with a strong sense of urgency.” Dr. Ginde and his team are now evaluating the efficacy of automatic oxygen therapy technology, with O2matic’s proprietary technology chosen for a multi-center study involving 300 patients. This study, named SAVE-O2 AI, and initiated in May 2024, aims to publish results by early 2026.